CytRx cancer drug shows promise in mid-stage study

LadRx

08/01/2015 14:33

Jan 8 (Reuters) - CytRx Corp  CYTR.O  said its cancer drug 
was effective against a type of skin cancer in HIV+ patients, 
sending its shares up 13 percent before the bell. 
    Interim data from an ongoing mid-stage study showed that the 
drug, aldoxorubicin, stopped tumor growth in HIV+ patients 
suffering from Kaposi's Sarcoma, the company said on Thursday. 
 ID:nPn6lNCJs  
    The U.S. Food and Drug Administration placed a hold on 
enrolling new patients in all clinical trials of aldoxorubicin 
in November, after a patient died.  ID:nL3N0T84DB  
 
 (Reporting by Rosmi Shaji in Bengaluru; Editing by Simon 
Jennings) 
 ((Rosmi.Shaji@thomsonreuters.com;)(Within U.S.+1 646 223 8780 
and outside U.S. +91 8067496753)(; Reuters Messaging:  
rosmi.shaji.thomsonreuters.com@reuters.net)) 
 
Keywords: CYTRX STUDY/